Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2) Peptide
MAP2K2
Reactivity: Human
Host: Synthetic
BP, WB, IHC
Catalog No. ABIN979766
Quick Overview for Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2) Peptide (ABIN979766)
Target
MEK2 (MAP2K2)
(Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2))
Origin
Human
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
-
-
Characteristics
- This is a synthetic peptide designed for use in combination with anti-MAP2K2 antibody (Catalog #: ARP48941_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handling Advice
- Avoid repeated freeze-thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- MEK2 (MAP2K2) (Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2))
-
Background
-
MAP2K2 is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in MAP2K2 gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, mental retardation, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene.The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, mental retardation, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.
Alias Symbols: MAPKK2, MEK2, MKK2, PRKMK2
Protein Interaction Partner: ARAF,MAPK1,MAPK3,RAF1,ARAF,BRAF,CASP9,CNKSR1,DUSP3,GRIN1,GRIN2D,MAP2K2,MAP2K2,MAPK1,MAPK3,MAPKSP1,RAF1,RGS12,ARAF,Flna,MAP2K2,MAPK1,MAPK3,MEPCE
Protein Size: 400 -
Molecular Weight
- 44 kDa
-
Gene ID
- 5605
-
NCBI Accession
- NM_030662, NP_109587
-
UniProt
- P36507
Target
-
You are here:
